Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**L-Leucyl-L-prolyl-L-prolyl-L-seryl-L-arginine** is a synthetic pentapeptide composed of the amino acids leucine, proline (twice), serine, and arginine. It is classified as a protein-based therapy under peptides. This compound is also known as the lymphocyte activating pentapeptide, suggesting potential immunomodulatory activity. However, detailed pharmacological mechanism of action and clinical indications are not well documented or publicly available. It appears to be an experimental biotech peptide with no established approved uses or marketed formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-Leucyl-L-prolyl-L-prolyl-L-seryl-L-arginine.